These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1788752)

  • 1. [Risk-benefit analysis of intra-arterial and intravenous PGE1 infusions in peripheral arterial occlusive disorders].
    Heidrich H
    Vasa Suppl; 1991; 33():346-7. PubMed ID: 1788752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Fibrinolytic activity, thrombocyte function and pharmacokinetics during intra-arterial or intravenous prostaglandin E1 infusion in patients with chronic arterial occlusive disease].
    Fitscha P; Simmet T; Peskar BA; Reuter H; Sinzinger H; Rogatti W; Tilsner V
    Wien Klin Wochenschr; 1988 Jul; 100(14):477-81. PubMed ID: 3062905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prostaglandin E1 in therapy of peripheral arterial occlusive disease].
    Sinzinger H; Rogatti W
    Wien Klin Wochenschr; 1991; 103(18):558-65. PubMed ID: 1750223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanisms of action of prostaglandin E1 in therapy of peripheral arterial occlusive diseases].
    Weiss T
    Vasa; 2003 Nov; 32(4):187-92. PubMed ID: 14694766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of intra-arterial and intravenous prostaglandin E1 infusions in occlusive arterial disease stage III/IV.
    Balzer K; Rogatti W; Rüttgerodt K
    Vasa Suppl; 1989; 28():31-8. PubMed ID: 2609242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of intra-arterial and intravenous PGE1 infusions on transcutaneous oxygen pressure in patients with critical ischemia of the extremities].
    Weiss T; Griesshaber J; Rogatti W; Kistner O; Hsu E; Jansen T; Diehm C
    Vasa Suppl; 1991; 33():341-2. PubMed ID: 1788749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intra-arterial and intravenous administration of prostaglandin E1 cause different changes to skin microcirculation in patients with peripheral arterial occlusive disease.
    Thum J; Caspary L; Creutzig A; Alexander K
    Vasa; 1998 May; 27(2):100-5. PubMed ID: 9612114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacologic concepts for clinical use of prostaglandin E1].
    Schrör K
    Vasa Suppl; 1991; 33():335-6. PubMed ID: 1788746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prostaglandin E1 in intermittent claudication].
    Scheffler P; de la Hamette D; Rogatti W
    Vasa Suppl; 1992; 35():147-8. PubMed ID: 1481022
    [No Abstract]   [Full Text] [Related]  

  • 10. [Intravenous and intra-arterial prostaglandin E1 treatment in patients with stage IIb arterial occlusive disease].
    Rudofsky G
    Vasa Suppl; 1988; 23():121-5. PubMed ID: 3206330
    [No Abstract]   [Full Text] [Related]  

  • 11. [Duplex ultrasound measurement of hemodynamic parameters at rest and following arterial stenosis: effect of intra-arterial infusion therapy with prostaglandin E1].
    Ranke C; Creutzig A; Alexander K
    Vasa Suppl; 1989; 27():353-5. PubMed ID: 2696104
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cardiopulmonary effects of prostaglandin E1. Aspects of drug safety].
    Heidrich H; Breddin HK; Rudofsky G; Scheffler P
    Med Klin (Munich); 1992 Mar; 87(3):123-30. PubMed ID: 1579089
    [No Abstract]   [Full Text] [Related]  

  • 13. [Randomized study comparing the clinical effectiveness of intravenous prostaglandin E1 and intravenous pentoxifylline in patients with Fontaine stage IIb arterial occlusive disease].
    Hepp W; von Bary S; Corovic D; Diehm C; Mühe E; Rudofsky G; Scheffler P; Trübestein G; Vogelpohl M
    Vasa Suppl; 1991; 33():348-9. PubMed ID: 1788753
    [No Abstract]   [Full Text] [Related]  

  • 14. [Placebo controlled study of the effect of intravenous PGE1 on macro- and microcirculation in patients with stage III/IV arterial occlusive disease].
    Scheffler P; de la Hamette D; Leipnitz G
    Vasa Suppl; 1991; 33():343-4. PubMed ID: 1788750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the effect of Lipo PGE1 and other related compounds on experimental peripheral arterial occlusive disease in rats.
    Goto J; Araki H; Otomo S; Aihara H
    Drugs Exp Clin Res; 1986; 12(11):917-21. PubMed ID: 3816509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Reflex oximetry for evaluating blood redistribution in patients with arterial occlusive disease treated with PGE1].
    Thum J; Caspary L; Creutzig A; Alexander K
    Vasa Suppl; 1992; 35():39-41. PubMed ID: 1481056
    [No Abstract]   [Full Text] [Related]  

  • 17. [Metabolism of intravenously administered prostaglandin E1 in patients with peripheral arterial occlusive disease].
    Hesse WH; Rudofsky G; Peskar BA
    Wien Klin Wochenschr; 1991; 103(18):554-7. PubMed ID: 1750222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostaglandin E1 incorporated in lipid microspheres (lipo PGE1).
    Otomo S; Mizushima Y; Aihara H; Yokoyama K; Watanabe M; Yanagawa A
    Drugs Exp Clin Res; 1985; 11(9):627-31. PubMed ID: 3880049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraarterial prostaglandine E1 in arterial occlusive disease (AOD) stages III and IV.
    Herold A; Bruch HP; Hörl M; Düsel W
    Prog Clin Biol Res; 1987; 242():439-44. PubMed ID: 2959966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic efficacy of intravenously applied prostaglandin E1.
    Scheffler P; de la Hamette D; Leipnitz G
    Vasa Suppl; 1989; 28():19-25. PubMed ID: 2609240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.